NKGen Biotech reported a net loss of $33.2 million for the third quarter of 2023, compared to a net loss of $6.7 million in the same period in 2022. As of September 30, 2023, the Company had total cash of $8.8 million. R&D expenses were $3.9 million, while G&A expenses were $3.0 million.